EADV 2023

AD and Eczema in 2023

Tapinarof on course to become a new topical treatment in AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, ADORING

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:43

Upadacitinib provides sustained skin clearance in adolescents and adults with AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, Measure Up; AD UP

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:39

Sustained deep clinical and itch responses with novel IL-13 inhibitor

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ADvocate; ADvantage

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:13

IL-13 inhibitor shows potential in atopic dermatitis

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA

Trial

Phase 2, TREK-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:08

Encouraging results for amlitelimab in atopic dermatitis

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, STREAM-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:03

Chronic hand eczema: patients share similar molecular signatures regardless of AD status

Presented By

Dr Jonathan Bar, Icahn School of Medicine at Mount Sinai, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:58

Severe hand eczema: dupilumab could be a future treatment

Presented By

Dr Laura Loman, University Medical Center Groningen, the Netherlands

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:55

Psoriasis News

Dual IL-17 blockade yields efficacy on joints and skin

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, BE OPTIMAL; BE COMPLETE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:27

High-dose subcutaneous spesolimab prevents GPP flares up to week 48

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 2, Effisayil 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:23

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis

Presented By

Prof. Bruce Strober, Yale University School of Medicine, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:01

First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:57

Hidradenitis Suppurativa: End of the Diagnostic and Therapeutic Draught

Skin tape stripping allows a novel precision medicine approach in HS

Presented By

Dr Kristina Navrazhina, Icahn School of Medicine at Mount Sinai, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:51

Nanobodies: A novel way to treat HS

Presented By

Prof. Brian Kirby, St. Vincent´s University Hospital, Ireland

Trial

Phase 2, MIRA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:48

Anti-IL17 blockade leads to maintained pain reduction in patients with HS

Presented By

Dr John Ingram, Cardiff University, UK

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:44

Vitiligo: Novel Treatment Options

JAK1 inhibition: a promising forthcoming treatment option in vitiligo

Presented By

Prof. Khaled Ezzedine, University Paris-Est Créteil, France

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:17

Vitiligo: Continuation of topical ruxolitinib successful in many initial non-responders

Presented By

Dr Albert Wolkerstorfer, Amsterdam University Medical Centers, the Netherlands

Trial

Phase 3, TRuE-V1; TRuE-V1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:10

Alopecia Areata: Novel Developments

JAK3/TEC inhibition achieves clinically meaningful responses in AA

Presented By

Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany

Trial

Phase 3, ALLEGRO-LT

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:31

Alopecia areata: remarkable regrowth rates with deuruxolitinib

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

Phase 3, THRIVE-AA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:28

Botanical drug solution improves hair regrowth in children and adolescents with AA

Presented By

Prof. Ulrike Blume-Peytavi, Charité – Berlin University Medicine, Germany

Trial

RAAINBOW

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:23

What’s New in Other Disease Entities

Nemolizumab shows high success rates in prurigo nodularis

Presented By

Prof. Sonja Ständer, Münster University Hospital, Germany

Trial

Phase 3, OLYMPIA 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:19

Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU

Presented By

Dr Ana Giménez-Arnau, Autonomous University and Pompeu Fabra University, Spain

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:13

Innovative wound gel reduces frequency of painful dressing changes in epidermolysis bullosa

Presented By

Prof. Dimitra Kiritsi, University of Freiburg, Germany

Trial

Phase 3, EASE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:08

Best of the Posters